Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial

Summary

Background An increased rate of brain atrophy is often observed in older subjects, in particular those who suffer from cognitive decline. Homocysteine is a risk factor for brain atrophy, cognitive impairment and dementia. Plasma concentrations of homocysteine can be lowered by dietary administration of B vitamins. Objective To determine whether supplementation with B vitamins that lower levels of plasma total homocysteine can slow the rate of brain atrophy in subjects with mild cognitive impairment in a randomised controlled trial (VITACOG, ISRCTN 94410159). Methods and Findings Single-center, randomized, double-blind controlled trial of high-dose folic acid, vitamins B6 and B12 in 271 individuals (of 646 screened) over 70 y old with mild cognitive impairment. A subset (187) volunteered to have cranial MRI scans at the start and finish of the study. Participants were randomly assigned to two groups of equal size, one treated with folic acid (0.8 mg/d), vitamin B12 (0.5 mg/d) and vitamin B6 (20 mg/d), the other with placebo; treatment was for 24 months. The main outcome measure was the change in the rate of atrophy of the whole brain assessed by serial volumetric MRI scans. Results A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial. The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63–0.90] in the active treatment group and 1.08% [0.94–1.22] in the placebo group (P = 0.001). The treatment response was related to baseline homocysteine levels: the rate of atrophy in participants with homocysteine >13 µmol/L was 53% lower in the active treatment group (P = 0.001). A greater rate of atrophy was associated with a lower final cognitive test scores. There was no difference in serious adverse events according to treatment category. Conclusions and Significance The accelerated rate of brain atrophy in elderly with mild cognitive impairment can be slowed by treatment with homocysteine-lowering B vitamins. Sixteen percent of those over 70 y old have mild cognitive impairment and half of these develop Alzheimer's disease. Since accelerated brain atrophy is a characteristic of subjects with mild cognitive impairment who convert to Alzheimer's disease, trials are needed to see if the same treatment will delay the development of Alzheimer's disease. Trial Registration Controlled-Trials.com http://www.controlled-trials.com/ISRCTN94410159/94410159

Related articles

• Anesthesia for Vascular Surgery

  This document discusses the role of anesthesia in vascular surgery, particularly focusing on the challenges presented by atherosclerosis and its implications for perioperative care. It highlights the importance of preoperative evaluation and pharmacologic management to optimize outcomes for patients undergoing surgery for peripheral vascular disease.

• Management of Patient with Neurologic Dysfunction

  This document provides comprehensive guidelines on the management of patients with altered levels of consciousness, detailing definitions, causes, clinical manifestations, and nursing interventions required for care. It incorporates assessment protocols, diagnostic procedures, and potential complications associated with neurologic dysfunction.

• BOX 16-5 Resources Related to Suicide Prevention

  This document provides an in-depth exploration of suicide, including its epidemiology, risk factors, and the application of nursing processes for care of suicidal patients. It discusses historical perspectives, cultural influences, and prevalent myths surrounding suicide while also emphasizing the importance of effective communication and assessment in preventing suicidal behavior.

• Milieu Therapy: The Therapeutic Community

  This chapter explores the concept of milieu therapy within the therapeutic community, discussing its goals, assumptions, and the roles of various healthcare workers, especially nurses, in creating a supportive therapeutic environment.

• Therapeutic Communication: Core Concepts

  This chapter delves into therapeutic communication techniques essential for nurses to effectively connect with patients in need of psychosocial intervention. It explores the impact of preexisting conditions on communication, nonverbal expressions, and methods such as active listening and motivational interviewing.